Complement C3 Binding Fragments for Deep Retinal Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-mediated diseases like geographic atrophy (GA) face challenges in delivering therapeutic molecules effectively to the deep layers of the retina due to physical barriers within the eye, with existing inhibitors like APL-2 having difficulty penetrating Bruch's membrane and providing insufficient lesion reduction.
Innovation Solution
Development of antigen-binding proteins, such as single-chain variable fragments (scFv) and VHH domains, that specifically target complement C3, inhibiting the Classical, Lectin, and Alternative pathways, with enhanced penetration capabilities to reach retinal tissues like the retinal pigment epithelium and choroid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If APL-2 is used to inhibit complement C3, then complement pathway inhibition is achieved, but penetration into deep retinal layers is insufficient
Solution Approach 1:
The patent applies segmentation by using small antibody fragments (scFv, VHH domains) instead of full-length antibodies or large PEGylated molecules like APL-2. These fragmented structures have reduced molecular weight and size, enabling them to penetrate Bruch's membrane and reach deep retinal layers while retaining complement C3 binding capability.
Solution Approach 2:
The patent changes the molecular parameters of the therapeutic agent by transitioning from large PEGylated molecules (350 kDa, 7.8 nm hydrodynamic radius) to small antibody fragments with molecular weights of 15-30 kDa and hydrodynamic radii of 2.5-3.5 nm. This parameter change enables penetration into previously inaccessible deep retinal tissues.
2Reliability
If APL-2 is administered, then complement inhibition occurs, but lesion growth reduction is modest
Solution Approach 1:
The patent applies local quality by concentrating the therapeutic effect in the specific location where it is needed most - the deep retinal layers and choroid. The small antibody fragments achieve high local concentrations in these previously inaccessible areas, producing superior clinical efficacy compared to systemic or superficial delivery methods.
Solution Approach 2:
The patent transitions from superficial or vascular delivery to deep tissue penetration by exploiting the size dimension. The small molecular dimensions of the antibody fragments (2.5-3.5 nm hydrodynamic radius) allow them to pass through Bruch's membrane and reach the retinal pigment epithelium and choroid, creating a new dimension of therapeutic access.
3Duration of action of stationary object
If PEGylation is applied to increase molecular weight, then circulation time is extended, but injection viscosity increases
Solution Approach 1:
The patent adopts a different strategy than extending circulation time through PEGylation. Instead, the small antibody fragments are designed for localized intraocular administration where they exert their effect directly at the site of action. This eliminates the need for prolonged circulation and avoids the viscosity problems associated with PEGylation.
Data Source
AI summary
Antigen-binding proteins with specificity to complement C3 and C3b are provided. Methods of treating complement C3-mediated diseases and disorders, methods of inhibiting the activity of the complement Classical pathway (CP), Lectin pathway (LP), and/or Alternative pathway (AP), and methods of inhibiting the activity of choroidal-localized complement C3 are also provided.